Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.

SZSE:301096 Stock Report

Market Cap: CN¥4.3b

Hangzhou Bio-Sincerity Pharma-TechLtd Future Growth

Future criteria checks 5/6

Hangzhou Bio-Sincerity Pharma-TechLtd is forecast to grow earnings and revenue by 33.3% and 25.9% per annum respectively. EPS is expected to grow by 33.1% per annum. Return on equity is forecast to be 12.9% in 3 years.

Key information

33.3%

Earnings growth rate

33.1%

EPS growth rate

Life Sciences earnings growth32.9%
Revenue growth rate25.9%
Future return on equity12.9%
Analyst coverage

Low

Last updated07 Nov 2024

Recent future growth updates

No updates

Recent updates

We Believe That Hangzhou Bio-Sincerity Pharma-TechLtd's (SZSE:301096) Weak Earnings Are A Good Indicator Of Underlying Profitability

Nov 04
We Believe That Hangzhou Bio-Sincerity Pharma-TechLtd's (SZSE:301096) Weak Earnings Are A Good Indicator Of Underlying Profitability

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SZSE:301096) Soars 30% But It's A Story Of Risk Vs Reward

Sep 30
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SZSE:301096) Soars 30% But It's A Story Of Risk Vs Reward

Market Cool On Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s (SZSE:301096) Earnings Pushing Shares 27% Lower

Jul 24
Market Cool On Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s (SZSE:301096) Earnings Pushing Shares 27% Lower

Solid Earnings May Not Tell The Whole Story For Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096)

Apr 29
Solid Earnings May Not Tell The Whole Story For Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096)

Should You Be Adding Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096) To Your Watchlist Today?

Mar 14
Should You Be Adding Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096) To Your Watchlist Today?

Earnings and Revenue Growth Forecasts

SZSE:301096 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,881503-4296324
12/31/20251,507395-4774504
12/31/20241,198307-2984314
9/30/20241,025212-693-126N/A
6/30/20241,119287-647-5N/A
3/31/20241,072287-751-28N/A
12/31/20231,017272-59890N/A
9/30/2023900250-520135N/A
6/30/2023786229-531154N/A
3/31/2023673210-388289N/A
1/1/2023607194-332259N/A
9/30/2022573192-319241N/A
6/30/2022479155-194224N/A
3/31/2022425126-178117N/A
12/31/2021374111-103145N/A
9/30/2021304101-167100N/A
6/30/202126785-20480N/A
3/31/202121155-22949N/A
12/31/202020757-20154N/A
12/31/201915644-3571N/A
12/31/201882112645N/A
12/31/201726-7N/A11N/A
6/30/2017308N/A11N/A
3/31/2017275N/A6N/A
12/31/2016243N/A2N/A
9/30/2016211N/A1N/A
6/30/201616-1N/A5N/A
3/31/2016162N/A4N/A
1/1/2016165N/A3N/A
12/31/20146-2N/A1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 301096's forecast earnings growth (33.3% per year) is above the savings rate (2.8%).

Earnings vs Market: 301096's earnings (33.3% per year) are forecast to grow faster than the CN market (26.2% per year).

High Growth Earnings: 301096's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 301096's revenue (25.9% per year) is forecast to grow faster than the CN market (13.8% per year).

High Growth Revenue: 301096's revenue (25.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 301096's Return on Equity is forecast to be low in 3 years time (12.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y